Conditional Similarity Codes – Guideline Analytics

This tables shows the use of n-grams (Search Term) and the Sorenson-Dice similarity coefficient (Similarity Measure) to retrieve a CUI code.
Document_ID	Conditional	Search Term	CUI	CUI Terms	Similarity Measure
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	history	C0019664	History	1.000
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	physical	C0205485	Physical	1.000
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	examination	C4321457	Examination	1.000
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	performed	C0884358	Performed	1.000
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	patients	C0030705	Patients	1.000
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	Heart	C0018787	Heart	1.000
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	development	C1527148	Development	1.000
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	progression	C0449258	Progression	1.000
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	physical examination	C0031809	Physical Examination	1.000
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	Heart Failure	C0018801	Heart failure	1.000
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	accelerate	C0521110	Accelerated	0.947
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	behaviors	C0004927	Behavior	0.933
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	history physical examination	C0150618	History and physical examination	0.906
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	obtained	C1301820	Obtain	0.833
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	thorough	C0263955	Thoroughpin	0.824
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	obtained	C1882120	Not Obtained	0.824
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	history physical examination	C0420160	History and physical examination, school	0.814
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	history physical examination	C0199190	History and physical examination, limited	0.800
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	history physical examination	C0199202	History and physical examination, license	0.800
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	history physical examination	C0199189	History and physical examination, complete	0.787
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	history physical examination	C0199193	History and physical examination, follow-up	0.787
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	presenting	C0426109	Caput presenting	0.783
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	history physical examination	C0420111	History and physical examination, insurance	0.774
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	history physical examination	C0199191	History and physical examination, diagnostic	0.762
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	history physical examination	C0199192	History and physical examination, monitoring	0.762
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	history physical examination	C0199198	History and physical examination, premarital	0.762
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	history physical examination	C0481846	History and physical examination, occupation	0.762
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	history physical examination	C0686935	History and physical examination, immigration	0.750
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	history physical examination	C1293835	Interview, history AND/OR physical examination	0.750
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	history physical	C0730554	History of physical abuse	0.743
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	examination	C0582103	Medical Examination	0.741
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	development	C0243107	development aspects	0.741
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	progression	C0242656	Disease Progression	0.741
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	history physical examination	C0686934	History and physical examination, pre-employment	0.727
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	presenting	C2735056	Presenting problem	0.720
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	history physical examination	C0199197	History and physical examination, administrative	0.716
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	examination	C0031809	Physical Examination	0.714
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	development	C0678723	Biologic Development	0.714
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	Failure	C0018801	Heart failure	0.706
32470	A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure.	history physical	C1299497	History and physical report	0.703
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	patients	C0030705	Patients	1.000
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	dilated	C0700124	Dilated	1.000
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	family	C0015576	Family	1.000
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	history	C0019664	History	1.000
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	diagnosis	C0011900	Diagnosis	1.000
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	familial	C0241888	Familial	1.000
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	family history	C0241889	Family history	1.000
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	dilated cardiomyopathy	C0007193	Cardiomyopathy, Dilated	0.950
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	cardiomyopathy	C1837350	No cardiomyopathy	0.929
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	dilated cardiomyopathy	C3532251	Fetal dilated cardiomyopathy	0.889
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	cardiomyopathy	C0878544	Cardiomyopathies	0.857
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	obtained	C1301820	Obtain	0.833
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	dilated cardiomyopathy	C0340427	Familial dilated cardiomyopathy	0.833
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	obtained	C1882120	Not Obtained	0.824
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	dilated cardiomyopathy	C0264795	Secondary dilated cardiomyopathy	0.816
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	establishing	C2364239	Establishing Trust	0.815
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	cardiomyopathy	C0007930	Chagas Cardiomyopathy	0.812
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	cardiomyopathy	C0007193	Cardiomyopathy, Dilated	0.788
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	establishing	C0443211	Established	0.762
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	establishing	C0150735	Establishing Rapport	0.759
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	dilated cardiomyopathy	C3668940	Dmd-Associated Dilated Cardiomyopathy	0.755
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	idiopathic dilated cardiomyopathy	C1449563	Cardiomyopathy, Familial Idiopathic	0.754
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	cardiomyopathy	C0007192	Cardiomyopathy, Alcoholic	0.743
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	dilated cardiomyopathy	C0349517	Dilated cardiomyopathy secondary to drug	0.727
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	cardiomyopathy	C0007196	Restrictive cardiomyopathy	0.703
32471	In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM.	dilated cardiomyopathy	C3532231	Dilated cardiomyopathy with genetic marker	0.702
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	Volume	C0449468	Volume	1.000
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	status	C0449438	Status	1.000
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	assessed	C1516048	Assessed	1.000
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	encounter	C1947978	Encounter	1.000
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	serial	C4554600	Serial	1.000
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	weight	C0043100	Weight	1.000
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	well	C3146287	Well	1.000
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	venous	C0348013	Venous	1.000
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	peripheral	C0205100	Peripheral	1.000
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	edema	C0013604	Edema	1.000
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	orthopnea	C0085619	Orthopnea	1.000
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	peripheral edema	C0085649	Peripheral edema	1.000
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	jugular venous pressure	C0428897	Jugular venous pressure	1.000
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	patient	C0030705	Patients	0.923
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	estimates	C0750572	Estimated	0.875
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	pressure	C1882095	No Pressure	0.875
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	patient encounter	C0582950	Patient encounter status	0.833
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	jugular venous	C0232133	Jugular venous pulse	0.828
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	pressure	C0001876	Air Pressure	0.824
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	venous pressure	C0429872	Venous mean pressure	0.800
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	patient encounter	C0422288	Letter encounter to patient	0.789
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	venous pressure	C0184275	Venous pressure monitor	0.788
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	venous pressure	C0428640	Central venous pressure	0.788
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	venous pressure	C0428897	Jugular venous pressure	0.788
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	includes	C4065484	diet includes	0.778
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	venous pressure	C0042486	Venous Blood Pressure	0.774
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	venous pressure	C0520855	Venous wedge pressure	0.774
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	presence	C0150312	Present	0.769
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	patient encounter	C0422305	Patient-initiated encounter	0.769
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	patient encounter	C0586016	Patient encounter procedure	0.769
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	venous pressure	C0232114	Abnormal venous pressure	0.765
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	assessment weight	C1444339	Weight control assessment	0.757
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	each	C1882141	Of Each	0.750
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	assessment	C0549070	Assessment: Coping	0.750
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	vital signs	C0150404	Taking vital signs	0.750
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	vital signs	C0277803	Normal vital signs	0.750
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	patient encounter	C0422286	Letter encounter from patient	0.750
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	jugular venous	C0428897	Jugular venous pressure	0.750
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	venous pressure	C0232115	Increased venous pressure	0.743
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	venous pressure	C0232116	Decreased venous pressure	0.743
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	pressure	C0005823	Blood Pressure	0.737
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	vital	C0442741	Non-vital	0.727
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	venous pressure	C0430477	Portal venous pressure test	0.722
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	vital signs	C1290982	Vital signs finding	0.720
32472	Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea.	weight	C0005910	Body Weight	0.714
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	risk	C0035647	Risk	1.000
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	useful	C3827682	Useful	1.000
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	patients	C0030705	Patients	1.000
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	Heart	C0018787	Heart	1.000
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	Heart Failure	C0018801	Heart failure	1.000
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	estimate	C0750572	Estimated	0.933
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	scores	C0449820	Score	0.889
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	hospitalized	C0008098	Child, Hospitalized	0.815
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	scores	C0871421	Z-score	0.800
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	hospitalized	C1546950	Caused hospitalized	0.786
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	estimate	C1441495	Best estimate	0.778
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	estimate	C1519101	Risk Estimate	0.778
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	mortality	C0008083	Child Mortality	0.762
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	hospitalized	C0749199	SYNCOPE HOSPITALIZED	0.759
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	hospitalized	C0870668	hospitalized patients	0.733
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	mortality	C0021278	Infant Mortality	0.727
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	subsequent	C4053982	Subsequent Relapse	0.720
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	scores	C0237855	Test scores	0.714
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	hospitalized	C0747908	PREGNANCY HOSPITALIZED	0.710
32473	Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure.	Failure	C0018801	Heart failure	0.706
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	laboratory	C0022877	Laboratory	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	evaluation	C0220825	Evaluation	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	patients	C0030705	Patients	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	Heart	C0018787	Heart	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	complete	C0205197	Complete	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	blood	C0005767	Blood	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	count	C0750480	Count	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	urinalysis	C0042014	Urinalysis	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	measurement	C0242485	Measurement	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	serum	C0229671	Serum	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	electrolytes	C0013832	Electrolytes	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	calcium	C0006675	Calcium	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	magnesium	C0024467	Magnesium	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	urea	C0041942	Urea	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	nitrogen	C0028158	Nitrogen	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	creatinine	C0010294	Creatinine	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	glucose	C0017725	Glucose	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	fasting	C0015663	Fasting	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	liver	C0023884	Liver	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	Heart Failure	C0018801	Heart failure	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	cell count	C0007584	Cell Count	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	liver function	C0232741	Liver function	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	blood cell count	C0005771	Blood Cell Count	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	blood urea nitrogen	C0600137	Blood Urea Nitrogen	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	fasting lipid profile	C0430044	Fasting lipid profile	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	liver function tests	C0023901	Liver Function Tests	1.000
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	measurement serum electrolytes	C0587355	Electrolytes measurement, serum	0.963
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	blood cell	C0005773	Blood Cells	0.941
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	hormone	C0019932	Hormones	0.923
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	serum creatinine	C0428282	Serum creatinine low	0.903
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	lipid	C0023779	Lipids	0.889
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	lipid	C0023767	Lipid A	0.889
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	Initial	C0205265	Initially	0.857
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	cell	C0007634	Cells	0.857
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	serum creatinine	C0600061	Serum creatinine level	0.848
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	measurement serum	C0036792	Copper measurement, serum	0.833
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	complete blood	C0009555	Complete Blood Count	0.828
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	function tests	C0023901	Liver Function Tests	0.828
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	measurement serum	C0427433	Serum TIBC measurement	0.824
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	serum creatinine	C0438244	Serum creatinine normal	0.824
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	serum creatinine	C0700225	Serum creatinine raised	0.824
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	urea nitrogen	C0600137	Blood Urea Nitrogen	0.815
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	measurement serum	C0202004	Estriol measurement, serum	0.811
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	measurement serum	C0202041	Glucose measurement, serum	0.811
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	function tests	C0022662	Kidney Function Tests	0.800
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	presenting	C0426109	Caput presenting	0.783
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	function	C0700205	Function Axis	0.778
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	serum creatinine	C0438243	Serum creatinine abnormal	0.778
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	function tests	C0430152	Gastric function tests	0.774
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	measurement serum	C0202020	Folic acid measurement, serum	0.769
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	measurement serum	C0201937	Carnitine measurement, serum	0.769
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	calcium magnesium	C0108127	calcium magnesium phosphate	0.769
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	calcium magnesium	C2604770	calcium magnesium carbonate	0.769
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	blood cell	C0005771	Blood Cell Count	0.762
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	fasting lipid	C0430044	Fasting lipid profile	0.759
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	lipid profile	C0430044	Fasting lipid profile	0.759
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	measurement serum	C0236281	Serum lithium measurement	0.757
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	profile	C0430041	Bone profile	0.750
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	magnesium blood	C0580559	Blood magnesium normal	0.750
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	function tests	C0430093	Chemical function tests	0.750
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	serum electrolytes	C0587355	Electrolytes measurement, serum	0.744
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	blood urea nitrogen	C0005845	Blood urea nitrogen measurement	0.744
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	measurement serum	C0236396	Serum cortisol measurement	0.737
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	blood urea	C0438241	Blood urea normal	0.727
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	function tests	C0024119	Pulmonary function tests	0.727
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	presenting	C2735056	Presenting problem	0.720
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	measurement serum	C0202125	Serum magnesium measurement	0.718
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	measurement serum	C0236479	Serum phenytoin measurement	0.718
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	measurement serum	C0302353	Serum potassium measurement	0.718
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	urea nitrogen	C3683557	Urea nitrogen (procedure)	0.710
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	Initial	C1705685	Initial Usage	0.706
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	Failure	C0018801	Heart failure	0.706
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	profile	C0072073	profile resin	0.706
32474	Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests.	magnesium blood	C0580560	Blood magnesium abnormal	0.706
32475	Serial monitoring, when indicated, should include serum electrolyte levels and renal function.	Serial	C4554600	Serial	1.000
32475	Serial monitoring, when indicated, should include serum electrolyte levels and renal function.	indicated	C1444656	Indicated	1.000
32475	Serial monitoring, when indicated, should include serum electrolyte levels and renal function.	serum	C0229671	Serum	1.000
32475	Serial monitoring, when indicated, should include serum electrolyte levels and renal function.	renal function	C0232804	Renal function	1.000
32475	Serial monitoring, when indicated, should include serum electrolyte levels and renal function.	electrolyte	C0013832	Electrolytes	0.952
32475	Serial monitoring, when indicated, should include serum electrolyte levels and renal function.	electrolyte	C3536863	Electrolyte [EPC]	0.870
32475	Serial monitoring, when indicated, should include serum electrolyte levels and renal function.	serum electrolyte levels	C1287347	Finding of serum electrolyte levels	0.824
32475	Serial monitoring, when indicated, should include serum electrolyte levels and renal function.	electrolyte levels	C0428284	Electrolyte levels - finding	0.821
32475	Serial monitoring, when indicated, should include serum electrolyte levels and renal function.	electrolyte	C0304459	Electrolyte agent	0.800
32475	Serial monitoring, when indicated, should include serum electrolyte levels and renal function.	monitoring	C0015945	Fetal Monitoring	0.783
32475	Serial monitoring, when indicated, should include serum electrolyte levels and renal function.	function	C0700205	Function Axis	0.778
32475	Serial monitoring, when indicated, should include serum electrolyte levels and renal function.	monitoring	C1283169	Monitoring - action	0.750
32475	Serial monitoring, when indicated, should include serum electrolyte levels and renal function.	electrolyte	C0013831	Electrolyte Balance	0.741
32476	A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure	lead	C0023175	Lead	1.000
32476	A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure	electrocardiogram	C0013798	Electrocardiogram	1.000
32476	A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure	performed	C0884358	Performed	1.000
32476	A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure	initially	C0205265	Initially	1.000
32476	A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure	patients	C0030705	Patients	1.000
32476	A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure	Heart	C0018787	Heart	1.000
32476	A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure	Heart Failure	C0018801	Heart failure	1.000
32476	A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure	lead electrocardiogram	C0179504	Electrocardiogram lead (device)	0.870
32476	A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure	lead electrocardiogram	C2960418	12 lead electrocardiogram at rest	0.833
32476	A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure	lead electrocardiogram	C0199557	Electrocardiogram, single lead	0.826
32476	A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure	presenting	C0426109	Caput presenting	0.783
32476	A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure	lead electrocardiogram	C0199558	Electrocardiogram, esophageal lead	0.760
32476	A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure	presenting	C2735056	Presenting problem	0.720
32476	A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure	lead electrocardiogram	C2960419	12 lead electrocardiogram during exercise	0.714
32476	A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure	Failure	C0018801	Heart failure	0.706
32477	Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure.	Screening	C1710032	Screening	1.000
32477	Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure.	hemochromatosis	C0018995	Hemochromatosis	1.000
32477	Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure.	patients	C0030705	Patients	1.000
32477	Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure.	present	C0150312	Present	1.000
32477	Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure.	Heart	C0018787	Heart	1.000
32477	Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure.	Heart Failure	C0018801	Heart failure	1.000
32477	Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure.	Screening hemochromatosis	C1303095	Hemochromatosis gene screening test	0.815
32477	Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure.	Failure	C0018801	Heart failure	0.706
32478	Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases.	Diagnostic	C0348026	Diagnostic	1.000
32478	Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases.	amyloidosis	C0002726	Amyloidosis	1.000
32478	Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases.	pheochromocytoma	C0031511	Pheochromocytoma	1.000
32478	Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases.	patients	C0030705	Patients	1.000
32478	Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases.	Heart	C0018787	Heart	1.000
32478	Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases.	clinical	C0205210	Clinical	1.000
32478	Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases.	suspicion	C0242114	Suspicion	1.000
32478	Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases.	Heart Failure	C0018801	Heart failure	1.000
32478	Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases.	diseases	C0012634	Disease	0.923
32478	Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases.	presenting	C0426109	Caput presenting	0.783
32478	Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases.	diseases	C0003462	Anus Diseases	0.778
32478	Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases.	suspicion these	C0242114	Suspicion	0.762
32478	Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases.	there clinical	C0205210	Clinical	0.737
32478	Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases.	presenting	C2735056	Presenting problem	0.720
32478	Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases.	Diagnostic	C0011900	Diagnosis	0.706
32478	Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases.	Failure	C0018801	Heart failure	0.706
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	patients	C0030705	Patients	1.000
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	risk	C0035647	Risk	1.000
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	Heart	C0018787	Heart	1.000
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	natriuretic	C0597421	natriuretic	1.000
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	screening	C1710032	Screening	1.000
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	cardiovascular	C3887460	Cardiovascular	1.000
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	specialist	C1611835	Specialist	1.000
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	useful	C3827682	Useful	1.000
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	development	C1527148	Development	1.000
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left	C0205091	Left	1.000
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	ventricular	C1522565	Ventricular	1.000
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	dysfunction	C3887504	Dysfunction	1.000
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	Heart Failure	C0018801	Heart failure	1.000
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	dysfunction systolic	C0749225	Systolic dysfunction	0.944
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction systolic	C1277187	Left ventricular systolic dysfunction	0.939
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	peptide	C0030956	Peptides	0.923
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	peptide	C0388060	peptide A	0.923
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	peptide	C0006558	C-Peptide	0.923
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction	C3532311	Fetal left ventricular dysfunction	0.909
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	ventricular dysfunction	C3532309	Fetal ventricular dysfunction	0.894
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction systolic	C3266750	Mild left ventricular systolic dysfunction	0.886
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction	C1997351	Left ventricular cardiac dysfunction	0.877
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	followed	C0332283	Followed by	0.875
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	natriuretic peptide	C0081880	Natriuretic Peptide, C-Type	0.872
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	ventricular dysfunction systolic	C1277187	Left ventricular systolic dysfunction	0.871
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction systolic	C3266753	Severe left ventricular systolic dysfunction	0.861
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	ventricular dysfunction systolic	C1562095	Right ventricular systolic dysfunction	0.857
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction	C1273070	Left ventricular diastolic dysfunction	0.847
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	diastolic	C0442709	end diastolic	0.842
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction systolic	C3266752	Moderate left ventricular systolic dysfunction	0.838
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction	C1277187	Left ventricular systolic dysfunction	0.828
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	followed	C4697860	Not Followed	0.824
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	systolic	C0489485	end systolic	0.824
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	ventricular dysfunction	C3532311	Fetal left ventricular dysfunction	0.824
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	ventricular dysfunction systolic	C3266750	Mild left ventricular systolic dysfunction	0.818
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	cardiovascular	C0007226	Cardiovascular system	0.812
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	ventricular dysfunction	C3532310	Fetal right ventricular dysfunction	0.808
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	diastolic	C0012000	Diastole	0.800
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	dysfunction systolic diastolic	C2711489	Combined systolic and diastolic dysfunction	0.800
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction systolic	C1271082	No evidence of left ventricular systolic dysfunction	0.795
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction systolic	C3698411	Asymptomatic left ventricular systolic dysfunction	0.795
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	ventricular dysfunction systolic	C3266753	Severe left ventricular systolic dysfunction	0.794
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	ventricular dysfunction	C1997351	Left ventricular cardiac dysfunction	0.792
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	developing	C0227024	Developing tooth	0.783
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	followed	C0559897	Diet followed	0.778
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	systolic	C0442710	Peak systolic	0.778
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular	C0080310	Left Ventricular Function	0.778
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction	C3266750	Mild left ventricular systolic dysfunction	0.774
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	ventricular dysfunction systolic	C3266752	Moderate left ventricular systolic dysfunction	0.771
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	systolic	C0039155	Systole	0.769
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	ventricular dysfunction	C1273070	Left ventricular diastolic dysfunction	0.764
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	biomarker	C2349100	Valid Biomarker	0.762
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular	C0199646	Left ventricular recording	0.757
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular	C0225897	Left ventricular structure	0.757
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular	C0232327	Left ventricular ST changes	0.757
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular	C0397282	Left ventricular operation	0.757
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction systolic	C1319789	Echocardiogram shows left ventricular systolic dysfunction	0.753
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	ventricular dysfunction	C1563062	Right ventricular diastolic dysfunction	0.750
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction	C3266753	Severe left ventricular systolic dysfunction	0.750
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	development	C0243107	development aspects	0.741
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	ventricular dysfunction	C1277187	Left ventricular systolic dysfunction	0.741
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction systolic	C2315697	Chronic systolic dysfunction of left ventricle	0.740
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	systolic	C0241320	systolic click	0.737
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular	C0344906	Left ventricular hypoplasia	0.737
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular	C0344911	Left ventricular dilatation	0.737
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular	C0397283	Open left ventricular biopsy	0.737
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	ventricular dysfunction systolic	C1271082	No evidence of left ventricular systolic dysfunction	0.730
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	ventricular dysfunction systolic	C3698411	Asymptomatic left ventricular systolic dysfunction	0.730
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	diastolic	C0232276	Diastolic rumble	0.727
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	ventricular dysfunction	C1562095	Right ventricular systolic dysfunction	0.727
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction	C3266752	Moderate left ventricular systolic dysfunction	0.727
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	ventricular dysfunction systolic	C1532382	No evidence of right ventricular systolic dysfunction	0.720
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular	C0149721	Left Ventricular Hypertrophy	0.718
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular	C0344905	Left ventricular abnormality	0.718
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	development	C0678723	Biologic Development	0.714
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction	C1532126	Left ventricular dysfunction monitoring invitation	0.714
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	Failure	C0018801	Heart failure	0.706
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction	C1446272	No evidence of left ventricular diastolic dysfunction	0.704
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction	C1532125	Left ventricular dysfunction monitoring first letter	0.704
32479	For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure.	left ventricular dysfunction	C1532128	Left ventricular dysfunction monitoring third letter	0.704
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	patients	C0030705	Patients	1.000
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	dyspnea	C0013404	Dyspnea	1.000
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	measurement	C0242485	Measurement	1.000
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	natriuretic	C0597421	natriuretic	1.000
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	useful	C3827682	Useful	1.000
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	diagnosis	C0011900	Diagnosis	1.000
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	exclusion	C2828389	Exclusion	1.000
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	Heart	C0018787	Heart	1.000
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	Heart Failure	C0018801	Heart failure	1.000
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	peptide	C0030956	Peptides	0.923
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	peptide	C0388060	peptide A	0.923
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	peptide	C0006558	C-Peptide	0.923
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	diagnosis exclusion	C4518809	Diagnosis of exclusion	0.889
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	measurement natriuretic peptide	C1095989	Brain natriuretic peptide measurement	0.885
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	natriuretic peptide	C0081880	Natriuretic Peptide, C-Type	0.872
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	measurement natriuretic peptide	C1446047	Plasma B natriuretic peptide measurement	0.857
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	presenting	C0426109	Caput presenting	0.783
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	biomarkers	C0041366	Biomarkers, Tumor	0.783
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	measurement natriuretic	C1095989	Brain natriuretic peptide measurement	0.741
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	presenting	C2735056	Presenting problem	0.720
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	biomarkers	C2735102	Cardiac biomarkers	0.720
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	measurement natriuretic	C1446047	Plasma B natriuretic peptide measurement	0.714
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	Failure	C0018801	Heart failure	0.706
32480	In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure.	measurement natriuretic	C0201900	Atrial natriuretic factor (ANF) measurement	0.702
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	Measurement	C0242485	Measurement	1.000
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	useful	C3827682	Useful	1.000
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	disease	C0012634	Disease	1.000
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	chronic	C0205191	chronic	1.000
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	Heart	C0018787	Heart	1.000
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	Heart Failure	C0018801	Heart failure	1.000
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	chronic Heart Failure	C0264716	Chronic heart failure	1.000
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	prognosis	C0278252	Prognosis bad	0.842
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	establishing	C2364239	Establishing Trust	0.815
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	prognosis	C0278250	Prognosis good	0.800
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	prognosis	C0278251	Fair prognosis	0.800
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	establishing	C0443211	Established	0.762
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	establishing	C0150735	Establishing Rapport	0.759
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	chronic Heart	C0264716	Chronic heart failure	0.759
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	chronic Heart	C1290386	Chronic heart disease	0.759
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	severity	C0439793	Severities	0.750
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	severity	C0457451	Severity score	0.737
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	prognosis	C0548855	fear of prognosis	0.727
32481	Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure.	Failure	C0018801	Heart failure	0.706
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	Measurement	C0242485	Measurement	1.000
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	baseline	C1442488	Baseline	1.000
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	natriuretic	C0597421	natriuretic	1.000
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	troponin	C0041199	Troponin	1.000
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	useful	C3827682	Useful	1.000
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	decompensated	C0205434	Decompensated	1.000
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	Heart	C0018787	Heart	1.000
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	Heart Failure	C0018801	Heart failure	1.000
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	cardiac troponin	C1305957	Cardiac troponin I	0.966
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	admission hospital	C0184666	Hospital admission	0.938
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	hospital	C0019994	Hospitals	0.933
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	peptide	C0030956	Peptides	0.923
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	peptide	C0388060	peptide A	0.923
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	peptide	C0006558	C-Peptide	0.923
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	admission	C0457453	On admission	0.889
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	admission	C4533677	at admission	0.889
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	establish	C0443211	Established	0.889
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	hospital	C4035588	Hospital-OR	0.875
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	natriuretic peptide	C0081880	Natriuretic Peptide, C-Type	0.872
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	admission	C0559269	Pre-admission	0.842
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	prognosis	C0278252	Prognosis bad	0.842
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	decompensated Heart Failure	C1827266	Decompensated chronic heart failure	0.836
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	establish	C0677368	Establish fees	0.800
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	prognosis	C0278250	Prognosis good	0.800
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	prognosis	C0278251	Fair prognosis	0.800
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	biomarkers	C0041366	Biomarkers, Tumor	0.783
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	admission hospital	C0184680	Hospital admission, special	0.769
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	establish	C0511063	Establish goals	0.762
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	admission hospital	C0184667	Hospital admission, elective	0.750
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	cardiac troponin	C3538889	Troponin T, Cardiac Muscle	0.743
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	admission hospital	C0184673	Emergency hospital admission	0.732
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	prognosis	C0548855	fear of prognosis	0.727
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	biomarkers	C2735102	Cardiac biomarkers	0.720
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	admission hospital	C0184694	Hospital admission, blood donor	0.714
32482	Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure.	Failure	C0018801	Heart failure	0.706
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	During	C0347984	During	1.000
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	Heart	C0018787	Heart	1.000
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	hospitalization	C0019993	Hospitalization	1.000
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	natriuretic	C0597421	natriuretic	1.000
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	level	C2946261	Level	1.000
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	useful	C3827682	Useful	1.000
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	Heart Failure	C0018801	Heart failure	1.000
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	peptide	C0030956	Peptides	0.923
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	peptide	C0388060	peptide A	0.923
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	peptide	C0006558	C-Peptide	0.923
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	establish	C0443211	Established	0.889
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	natriuretic peptide	C0081880	Natriuretic Peptide, C-Type	0.872
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	prognosis	C0278252	Prognosis bad	0.842
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	establish	C0677368	Establish fees	0.800
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	prognosis	C0278250	Prognosis good	0.800
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	prognosis	C0278251	Fair prognosis	0.800
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	natriuretic peptide level	C1319570	Serum pro-brain natriuretic peptide level	0.772
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	establish	C0511063	Establish goals	0.762
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	natriuretic peptide level	C1318675	Plasma pro-brain natriuretic peptide level	0.759
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	prognosis	C0548855	fear of prognosis	0.727
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	natriuretic peptide level	C1533071	N terminal pro-brain natriuretic peptide level	0.721
32483	During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis.	Failure	C0018801	Heart failure	0.706
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	patients	C0030705	Patients	1.000
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	chronic	C0205191	chronic	1.000
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	Heart	C0018787	Heart	1.000
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	measurement	C0242485	Measurement	1.000
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	other	C0205394	Other	1.000
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	myocardial	C1522564	Myocardial	1.000
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	fibrosis	C0016059	Fibrosis	1.000
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	additive	C0442796	Additive	1.000
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	risk	C0035647	Risk	1.000
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	stratification	C1514983	Stratification	1.000
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	Heart Failure	C0018801	Heart failure	1.000
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	chronic Heart Failure	C0264716	Chronic heart failure	1.000
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	considered	C0750591	consider	0.875
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	available	C1511733	Date Available	0.800
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	biomarkers	C0041366	Biomarkers, Tumor	0.783
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	myocardial	C0027061	Myocardium	0.778
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	chronic Heart	C0264716	Chronic heart failure	0.759
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	chronic Heart	C1290386	Chronic heart disease	0.759
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	considered	C3840836	Considered futile	0.750
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	available	C0557465	No help available	0.727
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	clinically	C0856661	Clinically shocked	0.720
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	biomarkers	C2735102	Cardiac biomarkers	0.720
32484	In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification.	Failure	C0018801	Heart failure	0.706
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	Patients	C0030705	Patients	1.000
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	Heart	C0018787	Heart	1.000
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	acute	C0205178	acute	1.000
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	decompensated	C0205434	Decompensated	1.000
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	chest	C0817096	Chest	1.000
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	size	C0456389	size	1.000
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	congestion	C0700148	Congestion	1.000
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	alternative	C1523987	Alternative	1.000
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	other	C0205394	Other	1.000
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	symptoms	C1457887	Symptoms	1.000
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	Heart Failure	C0018801	Heart failure	1.000
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	pulmonary congestion	C0242073	Pulmonary congestion	1.000
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	diseases	C0012634	Disease	0.923
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	patient	C0030705	Patients	0.923
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	suspected	C1997218	NOT suspected	0.842
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	decompensated Heart Failure	C1827266	Decompensated chronic heart failure	0.836
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	assess	C1516048	Assessed	0.833
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	detect	C1330713	EZ Detect	0.833
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	contribute	C1880177	Contribution	0.800
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	presenting	C0426109	Caput presenting	0.783
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	diseases	C0003462	Anus Diseases	0.778
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	cardiac pulmonary	C0398350	Acute cardiac pulmonary edema	0.750
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	presenting	C2735056	Presenting problem	0.720
32485	Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms.	Failure	C0018801	Heart failure	0.706
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	performed	C0884358	Performed	1.000
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	during	C0347984	During	1.000
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	evaluation	C0220825	Evaluation	1.000
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	patients	C0030705	Patients	1.000
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	Heart	C0018787	Heart	1.000
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	ventricular	C1522565	Ventricular	1.000
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	size	C0456389	size	1.000
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	motion	C0026597	Motion	1.000
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	Heart Failure	C0018801	Heart failure	1.000
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	dimensional	C1705052	2-Dimensional	0.952
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	ventricular function	C0080310	Left Ventricular Function	0.900
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	ventricular function	C0080311	Ventricular Function, Right	0.878
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	echocardiogram	C0013516	Echocardiography	0.857
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	initial	C0205265	Initially	0.857
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	echocardiogram	C2243117	Echocardiogram (image)	0.839
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	assess	C1516048	Assessed	0.833
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	valve function	C0588136	Heart valve function	0.828
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	echocardiogram	C0436484	Echocardiogram normal	0.812
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	echocardiogram	C0743380	echocardiogram result	0.812
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	dimensional	C0450363	Three-dimensional	0.800
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	valve function	C0428789	Aortic valve function	0.800
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	valve function	C0428799	Mitral valve function	0.800
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	presenting	C0426109	Caput presenting	0.783
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	function	C0700205	Function Axis	0.778
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	ventricular function	C1287715	Left ventricular function - finding	0.766
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	echocardiogram	C0476369	Echocardiogram abnormal	0.765
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	echocardiogram	C1319340	Echocardiogram declined	0.765
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	ventricular function	C0553982	Impaired left ventricular function	0.750
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	ventricular function	C1287720	Right ventricular function - finding	0.750
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	echocardiogram	C1303038	Echocardiogram requested	0.743
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	thickness	C0239600	FINGER THICKNESS	0.727
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	thickness	C0332524	Normal thickness	0.727
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	thickness	C0423756	Thickness of skin	0.727
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	valve function	C0428814	Pulmonary valve function	0.727
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	valve function	C0428815	Tricuspid valve function	0.727
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	presenting	C2735056	Presenting problem	0.720
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	wall motion	C0232167	Cardiac wall motion	0.720
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	echocardiogram	C0920208	Echocardiography, Stress	0.706
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	Doppler	C0430489	Laser doppler	0.706
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	initial	C1705685	Initial Usage	0.706
32486	A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function.	Failure	C0018801	Heart failure	0.706
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	Repeat	C0205341	Repeat	1.000
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	measurement	C0242485	Measurement	1.000
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	useful	C3827682	Useful	1.000
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	information	C1533716	Information	1.000
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	patients	C0030705	Patients	1.000
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	Heart	C0018787	Heart	1.000
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	significant	C0750502	Significant	1.000
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	clinical	C0205210	Clinical	1.000
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	status	C0449438	Status	1.000
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	event	C0441471	Event	1.000
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	effect	C1280500	Effect	1.000
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	Heart Failure	C0018801	Heart failure	1.000
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	clinical status	C0449440	Clinical status	1.000
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	cardiac function	C0232164	Cardiac function	1.000
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	received	C1514756	Receive	0.923
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	device	C0699733	Devices	0.909
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	treatment	C0746919	NO TREATMENT	0.889
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	received	C1709850	Received By	0.875
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	structural	C0678594	structure	0.824
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	received	C0729795	Fax received	0.824
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	structural	C0017366	Structural gene	0.818
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	remodeling	C0085268	Bone remodeling	0.818
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	therapy	C0003827	Art Therapy	0.800
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	received	C1115441	Date received	0.778
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	function	C0700205	Function Axis	0.778
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	recovered	C1546957	Fully recovered	0.762
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	treatment	C3161471	Treatment Study	0.762
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	treatment	C3538994	Treatment Epoch	0.762
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	severity	C0439793	Severities	0.750
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	structural	C0026349	Models, Structural	0.750
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	remodeling	C1820201	tissue remodeling	0.750
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	provide	C0593738	Provide Xtra	0.750
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	therapy	C0010412	Cold Therapy	0.750
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	severity	C0457451	Severity score	0.737
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	candidates	C1549320	QBP _ Find candidates	0.720
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	device therapy	C3880777	Dry salt therapy device	0.710
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	device therapy	C3881193	Cupping therapy device	0.710
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	Failure	C0018801	Heart failure	0.706
32487	Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy.	therapy	C0010962	Dance Therapy	0.706
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	Noninvasive	C2986496	Noninvasive	1.000
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	myocardial	C1522564	Myocardial	1.000
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	ischemia	C0022116	Ischemia	1.000
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	patients	C0030705	Patients	1.000
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	Heart	C0018787	Heart	1.000
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	known	C0205309	Known	1.000
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	eligible	C1548635	Eligible	1.000
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	myocardial ischemia	C0151744	Myocardial Ischemia	1.000
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	Heart Failure	C0018801	Heart failure	1.000
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	patient	C0030705	Patients	0.923
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	revascularization	C0472662	Limb revascularization	0.889
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	revascularization	C0581603	Revascularization - action	0.842
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	revascularization	C0472666	Revascularization of hand	0.842
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	revascularization	C0472672	Revascularization of foot	0.842
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	detect	C1330713	EZ Detect	0.833
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	revascularization	C0472667	Revascularization of thumb	0.821
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	revascularization	C0007794	Cerebral Revascularization	0.800
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	revascularization	C0472668	Revascularization of finger	0.800
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	presenting	C0426109	Caput presenting	0.783
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	revascularization	C0472665	Revascularization of forearm	0.780
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	myocardial	C0027061	Myocardium	0.778
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	viability	C0015954	Fetal Viability	0.762
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	viability	C0449583	Viability of gut	0.762
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	viability	C1300991	Tumor viability	0.762
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	viability	C1442040	Viability count	0.762
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	revascularization	C0027056	Myocardial Revascularization	0.762
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	viability	C1449935	Tissue Viability	0.727
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	revascularization	C0472582	Revascularization for impotence	0.727
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	presenting	C2735056	Presenting problem	0.720
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	angina	C0019338	Herpangina	0.714
32488	Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind.	Failure	C0018801	Heart failure	0.706
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	Heart	C0018787	Heart	1.000
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	patients	C0030705	Patients	1.000
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	Heart Failure	C0018801	Heart failure	1.000
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	revascularization	C0472662	Limb revascularization	0.889
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	revascularization	C0581603	Revascularization - action	0.842
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	revascularization	C0472666	Revascularization of hand	0.842
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	revascularization	C0472672	Revascularization of foot	0.842
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	select	C1651012	Select-OB	0.833
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	revascularization	C0472667	Revascularization of thumb	0.821
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	revascularization	C0007794	Cerebral Revascularization	0.800
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	revascularization	C0472668	Revascularization of finger	0.800
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	revascularization Heart	C0189976	Indirect heart revascularization	0.800
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	revascularization	C0472665	Revascularization of forearm	0.780
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	planning	C0008866	City Planning	0.778
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	select	C2730299	PNV Select	0.769
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	Viability	C0015954	Fetal Viability	0.762
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	Viability	C0449583	Viability of gut	0.762
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	Viability	C1300991	Tumor viability	0.762
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	Viability	C1442040	Viability count	0.762
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	revascularization	C0027056	Myocardial Revascularization	0.762
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	assessment	C0549070	Assessment: Coping	0.750
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	Viability	C1449935	Tissue Viability	0.727
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	revascularization	C0472582	Revascularization for impotence	0.727
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	revascularization Heart	C0190058	Grafting of heart for revascularization	0.727
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	revascularization Heart	C0027056	Myocardial Revascularization	0.723
32489	Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD.	Failure	C0018801	Heart failure	0.706
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	useful	C3827682	Useful	1.000
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	volume	C0449468	Volume	1.000
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	echocardiography	C0013516	Echocardiography	1.000
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	Radionuclide ventriculography	C0034610	Radionuclide Ventriculography	1.000
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	magnetic resonance imaging	C0024485	Magnetic Resonance Imaging	1.000
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	ventriculography	C0846023	Right ventriculography	0.857
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	assess	C1516048	Assessed	0.833
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	magnetic resonance	C0024485	Magnetic Resonance Imaging	0.821
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	ventriculography	C0596683	Cardiac ventriculography	0.811
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	magnetic	C0563532	Magnetism	0.800
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	ventriculography	C0007800	Cerebral Ventriculography	0.789
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	resonance imaging	C0024485	Magnetic Resonance Imaging	0.789
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	magnetic	C0427170	Magnetic gait	0.778
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	magnetic	C0681512	magnetic tape	0.778
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	ventriculography	C0042516	Ventriculography, First-Pass	0.769
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	resonance	C0314720	Vocal resonance	0.762
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	Radionuclide	C0034606	Radionuclide Imaging	0.759
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	ventriculography	C0412219	Left ventriculogram	0.750
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	magnetic resonance	C0243032	Magnetic Resonance Angiography	0.744
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	magnetic resonance	C0336660	Magnetic resonance imaging unit	0.744
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	magnetic	C0439876	Magnetic metal	0.737
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	magnetic resonance	C0024487	Magnetic Resonance Spectroscopy	0.727
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	ventriculography	C0034610	Radionuclide Ventriculography	0.714
32490	Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate.	resonance imaging	C0336660	Magnetic resonance imaging unit	0.714
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	myocardial	C1522564	Myocardial	1.000
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	burden	C2828008	Burden	1.000
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	Magnetic resonance imaging	C0024485	Magnetic Resonance Imaging	1.000
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	Magnetic resonance	C0024485	Magnetic Resonance Imaging	0.821
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	Magnetic	C0563532	Magnetism	0.800
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	resonance imaging	C0024485	Magnetic Resonance Imaging	0.789
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	Magnetic	C0427170	Magnetic gait	0.778
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	Magnetic	C0681512	magnetic tape	0.778
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	myocardial	C0027061	Myocardium	0.778
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	resonance	C0314720	Vocal resonance	0.762
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	processes	C0018265	Group Processes	0.762
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	Magnetic resonance	C0243032	Magnetic Resonance Angiography	0.744
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	Magnetic resonance	C0336660	Magnetic resonance imaging unit	0.744
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	Magnetic	C0439876	Magnetic metal	0.737
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	infiltrative	C1168158	Infiltrative erythema	0.733
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	assessing	C0548299	Assessing Oedema	0.727
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	assessing	C1999048	Assessing Coping	0.727
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	assessing	C2364225	Assessing Denial	0.727
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	processes	C0025361	Mental Processes	0.727
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	Magnetic resonance	C0024487	Magnetic Resonance Spectroscopy	0.727
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	resonance imaging	C0336660	Magnetic resonance imaging unit	0.714
32491	Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden.	infiltrative	C3842356	Diffusely infiltrative	0.710
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	Routine	C0205547	Routine	1.000
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	repeat	C0205341	Repeat	1.000
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	measurement	C0242485	Measurement	1.000
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	clinical	C0205210	Clinical	1.000
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	status	C0449438	Status	1.000
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	performed	C0884358	Performed	1.000
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	clinical status	C0449440	Clinical status	1.000
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	status change	C0442739	No status change	0.917
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	treatment	C0746919	NO TREATMENT	0.889
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	function assessment	C2732244	School function assessment	0.850
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	measurement function	C2711919	Measurement of renal function	0.791
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	function	C0700205	Function Axis	0.778
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	interventions	C0886296	Nursing interventions	0.774
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	treatment	C3161471	Treatment Study	0.762
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	treatment	C3538994	Treatment Epoch	0.762
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	interventions	C0010332	Crisis Intervention	0.759
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	change treatment	C0419902	Endocrine treatment change	0.757
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	function assessment	C2959524	School function assessment score	0.756
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	assessment	C0549070	Assessment: Coping	0.750
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	interventions	C1273869	Intervention regimes	0.733
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	absence	C0332197	Absent	0.727
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	function assessment	C4518444	Assessment of fine motor function	0.711
32492	Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed.	interventions	C3542921	CDISC Interventions Class	0.706
32493	Invasive hemodynamic monitoring with a pulmonary artery catheter should be performed to guide therapy in patients who have respiratory distress or clinical evidence of impaired perfusion in whom the adequacy or excess of intracardiac filling pressures cannot be determined from clinical assessment.	Invasive	C0205281	Invasive	1.000
32493	Invasive hemodynamic monitoring with a pulmonary artery catheter should be performed to guide therapy in patients who have respiratory distress or clinical evidence of impaired perfusion in whom the adequacy or excess of intracardiac filling pressures cannot be determined from clinical assessment.	performed	C0884358	Performed	1.000
32493	Invasive hemodynamic monitoring with a pulmonary artery catheter should be performed to guide therapy in patients who have respiratory distress or clinical evidence of impaired perfusion in whom the adequacy or excess of intracardiac filling pressures cannot be determined from clinical assessment.	patients	C0030705	Patients	1.000
32493	Invasive hemodynamic monitoring with a pulmonary artery catheter should be performed to guide therapy in patients who have respiratory distress or clinical evidence of impaired perfusion in whom the adequacy or excess of intracardiac filling pressures cannot be determined from clinical assessment.	respiratory	C0521346	respiratory	1.000
32493	Invasive hemodynamic monitoring with a pulmonary artery catheter should be performed to guide therapy in patients who have respiratory distress or clinical evidence of impaired perfusion in whom the adequacy or excess of intracardiac filling pressures cannot be determined from clinical assessment.	distress	C0231303	Distress	1.000
32493	Invasive hemodynamic monitoring with a pulmonary artery catheter should be performed to guide therapy in patients who have respiratory distress or clinical evidence of impaired perfusion in whom the adequacy or excess of intracardiac filling pressures cannot be determined from clinical assessment.	clinical	C0205210	Clinical	1.000
32493